Santacruzamate A

Ultrapotent HDAC2 inhibitor

Product Specifications

Background

Santacruzamate A is a highly potent and selective inhibitor of HDAC2 isolated from the Panamanian marine cyanobacterium cf. Symploca (IC50=0.119 and 434 nM for HDAC2 and HDAC6 respectively) (1). It induces apoptosis and cancer cell death only in combination with other HDAC1 inhibitors (2). It has been been investigated as a potential therapeutic agent for breast cancer (3). Attenuates A fragment (A25-35)-induced toxicity in PC12 cells by enhancing ER stress tolerance4. Ameliorates Alzheimer’s disease-like pathology in mouse models (4).

Product Name Alternative

N-[4-Oxo-4-[(2-phenylethyl)amino]butyl]-carbamic acid, ethyl ester

UNSPSC

41116105

Source

Synthetic

Purity

>98% (TLC); NMR (Conforms)

Weight

0.005

Format

Off-white powder

Solubility

May be dissolved in DMSO (25 mg/ml); or Ethanol (20 mg/ml)

Molecular Formula

C15H22N2O3

Molecular Weight

278.4

Precautions

Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

References & Citations

1. Pavlik C.M., et al. (2013) J. Nat. Prod. 76:2026 2.Zhou et al. H., (2018) Cell Prolif. 51(3):e12477 3. Damaskos C., et al. (2017) Anticancer Res. 37:35 4.Chen L., et al. (2019) Front. Cell. Neurosci. 13:61